Premium
Use of 13‐Valent Pneumococcal Conjugate Vaccine and 23‐Valent Pneumococcal Polysaccharide Vaccine for Adults With Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Author(s) -
Nancy M. Bennett,
Cynthia G. Whitney,
Matt Moore,
Tamara Pilishvili,
Kathleen L. Dooling
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12073
Subject(s) - medicine , advisory committee , immunization , pneumococcal conjugate vaccine , pneumococcal disease , conjugate vaccine , pneumococcal polysaccharide vaccine , pneumococcal vaccine , pediatrics , immunology , streptococcus pneumoniae , microbiology and biotechnology , antigen , public administration , political science , biology , antibiotics
This document details the new recommendation for utilizing the 13‐valent pneumococcal conjugate vaccine in place of the 23‐valent polysaccharide vaccine in transplant recipients and the majority of candidates.